Status and phase
Conditions
Treatments
About
This phase 1 study is to evaluate the safety and tolerability of YB-1113 administered via intravenous (IV) infusion in the treatment of premature ovarian insufficiency (POI).
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Key Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
6 participants in 2 patient groups
Loading...
Central trial contact
Jennifer Wang
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal